Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674752 · ClinicalTrials.gov registry record · Phase 3
A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia
A Phase 3 study of Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
- 4
- Study locations
NCT00674752: Completed Phase 3 study of Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00674752 is a Phase 3 study of Transient Insomnia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 377 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674752, a Phase 3 study of Transient Insomnia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (4)
Florida
- Pfizer Investigational Site - Miami
Georgia
- Pfizer Investigational Site - Atlanta
Kansas
- Pfizer Investigational Site - Overland Park
Ohio
- Pfizer Investigational Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-08 |
| Phase | Phase 3 |
What the finished NCT00674752 record still lists
NCT00674752 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Transient Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00674752 reports a single indexed study location in Florida, Georgia, Kansas.
Frequently Asked Questions
What is clinical trial NCT00674752 about?
NCT00674752 is a clinical study titled "A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia". The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.
What is the current status of trial NCT00674752?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2006-03. Estimated completion is 2006-08.
What conditions does trial NCT00674752 study?
This clinical trial studies the following conditions: Transient Insomnia.
What interventions are being tested in trial NCT00674752?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00674752?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00674752 being conducted?
This trial has 4 study locations across Florida, Georgia, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transient Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00674752's enrollment target sits among peer trials
377 988th of 2000 higher than 1,013 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia